Headlines Covid-19 Specialties Trending Feeds Videos

The combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability...

The FDA has issued a complete response letter to Incyte Corporation stating that it cannot approve the biologics license application for retifanlimab for use...

  • The @US_FDA issued a complete response letter to Incyte Corporation stating that it cannot approve the BLA for retifanlimab for use in patients w/ locally advanced or metastatic SCAC who are intolerant of platinum-based chemotherapy #oncology https://t.co/hX8WKtif6d - view on twitter

Health Canada has approved the BTK inhibitor zanubrutinib for use in the treatment of adult patients with mantle cell lymphoma who have previously received...

Karim Masrouha, MD, discusses the challenges of surgically removing chordoma...

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in...

It is difficult to dispute that these are troubling times for government officials and public health...

Joseph W. Kim, MD, Associate Professor of Medicine at Yale Cancer Center, has received a 2021 Cancer Clinical Investigator Team Leadership Award from the...

Lyndsay Willmott, MD, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing...

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in...

Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast...